Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Exosome Diagnostics Raises $27 Million in Series B Financing

Published: Wednesday, March 12, 2014
Last Updated: Wednesday, March 12, 2014
Bookmark and Share
Proceeds will be used to advance development of the company's proprietary platform technology and commercial programs.

Exosome Diagnostics announce the initial close of its Series B financing round with the raising of $27 million. 

Key Points:

  • Co-leading the financing were new investors QIAGEN and Arcus Ventures
  • New participating investors included Tiger Partners L.P. (an investment vehicle managed by Julian H. Robertson, Jr.), CD Ventures and Monashee Capital
  • Existing participating investors included NGN Capital and Forbion Capital Partners
  • Steven Soignet, M.D., general partner at Arcus Ventures and former faculty member at Memorial Sloan Kettering Cancer Center, to join Exosome's Board of Directors
  • Use of proceeds will include:

1. Launch of the first clinical diagnostic product in the U.S. planned for 2014; EXO106 is a diagnostic test using a non-invasive urine sample which could potentially reduce the number of unnecessary prostate biopsies in patients with an elevated PSA

2. Development under an expanded collaboration with QIAGEN of a blood-based diagnostic test measuring an actionable mutation in non-small cell lung cancer; EXO501 is expected to provide repeated, non-invasive assessment of tumor mutation status

3. Development of a blood-based, multi-gene clinically actionable biomarker panel for use in oncology applications; EXO1000 expected to measure key gene mutations and gene expression levels routinely used in oncology

4. Global launch of exoRNeasy® research kits for RNA extraction from blood serum/plasma targeted for Q2 2014; exoRNeasy® will carry the QIAGEN and Exosome Diagnostics brand names

5. Continued research and development of the Exosome Diagnostics proprietary technology platform

  • Leerink Swann served as financial advisor and placement agent to Exosome Diagnostics in connection with the Series B private placement

"Our proprietary fluid-based technology platform represents a significant advance in delivering molecular diagnostic information without the patient needing to undergo an invasive tissue biopsy. 2014 will be a transformative year as we bring our first commercialized products to market," James McCullough, chief executive officer of Exosome Diagnostics

"Exosome Diagnostics technology will advance cancer care by allowing the collection of longitudinal molecular information that can potentially improve the use of cancer therapeutics and may serve as a method to diagnose and assess for recurrence of disease," Steven Soignet, M.D., general partner of Arcus Ventures.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!